These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11366942)

  • 21. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Salvage therapy for HIV infection].
    Salzberger B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():32-7. PubMed ID: 16385870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A virological perspective on resistance in highly treatment-experienced patients.
    Geretti AM
    J HIV Ther; 2002 Nov; 7(4):97-101. PubMed ID: 12733608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to antiretrovirals in HIV-infected pregnant women.
    Weinberg A; Forster-Harwood J; McFarland EJ; Pappas J; Davies JK; Kinzie K; Barr EA; Paul SM; Salbenblatt CR; Soda E; Vazquez A; Levin MJ
    J Clin Virol; 2009 May; 45(1):39-42. PubMed ID: 19329355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug resistance in antiretroviral therapy of HIV infection].
    Oette M; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA clarifies rules, allows combining antiretrovirals in clinical trials. Food and Drug Administration.
    AIDS Treat News; 1999 Nov; (No 331):5-6. PubMed ID: 11367127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Lagnese M; Daar ES
    Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New knowledge and new challenges: 4th National Conference on Retroviruses & Opportunistic Infections].
    Agosto M; Ehara R
    Sidahora; 1997; ():18-21. PubMed ID: 11364490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activism today: the Coalition for Salvage Therapy. Interview with Linda Grinberg. Interview by John S. James.
    Grinberg L
    AIDS Treat News; 1999 Nov; (No 330):2-4. PubMed ID: 11367171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
    Wepner U
    MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
    [No Abstract]   [Full Text] [Related]  

  • 37. [Salvage therapy in HIV infection].
    Salzberger B
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New weapons on the way in battle against mutating HIV.
    AIDS Alert; 2000 Jan; 15(1):8-9. PubMed ID: 11366361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV resistance testing proves its value.
    Proj Inf Perspect; 1999 Sep; (28):14. PubMed ID: 11367356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.